EA202091239A1 - Слитый белок на основе терапевтического фермента, имеющий новую структуру, и его применение - Google Patents

Слитый белок на основе терапевтического фермента, имеющий новую структуру, и его применение

Info

Publication number
EA202091239A1
EA202091239A1 EA202091239A EA202091239A EA202091239A1 EA 202091239 A1 EA202091239 A1 EA 202091239A1 EA 202091239 A EA202091239 A EA 202091239A EA 202091239 A EA202091239 A EA 202091239A EA 202091239 A1 EA202091239 A1 EA 202091239A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fusion protein
application
new structure
protein based
therapeutic enzyme
Prior art date
Application number
EA202091239A
Other languages
English (en)
Inventor
Ый Чжун Чон
Джин Ён Ким
Ин Юнг Чой
Сун Юб Чун
Original Assignee
Ханми Фарм. Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ханми Фарм. Ко., Лтд. filed Critical Ханми Фарм. Ко., Лтд.
Publication of EA202091239A1 publication Critical patent/EA202091239A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к слитому белку, представляющему слияние между димерным терапевтическим ферментом и областью Fc иммуноглобулина, способу его получения и композиции, содержащей слитый белок.
EA202091239A 2017-12-22 2018-12-21 Слитый белок на основе терапевтического фермента, имеющий новую структуру, и его применение EA202091239A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170178378 2017-12-22
PCT/KR2018/016487 WO2019125059A1 (ko) 2017-12-22 2018-12-21 신규한 구조를 갖는 치료학적 효소 융합단백질 및 이의 용도

Publications (1)

Publication Number Publication Date
EA202091239A1 true EA202091239A1 (ru) 2020-09-09

Family

ID=66993643

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091239A EA202091239A1 (ru) 2017-12-22 2018-12-21 Слитый белок на основе терапевтического фермента, имеющий новую структуру, и его применение

Country Status (17)

Country Link
US (1) US20210009984A1 (ru)
EP (1) EP3708661A4 (ru)
JP (1) JP7403455B2 (ru)
KR (2) KR102588611B1 (ru)
CN (1) CN111511910A (ru)
AR (1) AR113430A1 (ru)
AU (1) AU2018388331A1 (ru)
BR (1) BR112020012346A2 (ru)
CA (1) CA3086474A1 (ru)
EA (1) EA202091239A1 (ru)
IL (1) IL275248A (ru)
MX (1) MX2020006635A (ru)
NZ (1) NZ765453A (ru)
PH (1) PH12020550927A1 (ru)
SG (1) SG11202005510SA (ru)
TW (1) TW201934753A (ru)
WO (1) WO2019125059A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3895708A3 (en) * 2019-08-07 2022-01-19 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
CA3197506A1 (en) 2020-10-14 2022-04-21 Denali Therapeutics Inc. Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof
WO2022103221A1 (ko) * 2020-11-13 2022-05-19 한미약품 주식회사 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신장질환 예방 및 치료 용도
CN116419759A (zh) * 2020-11-13 2023-07-11 韩美药品株式会社 治疗酶融合蛋白在预防和治疗由法布里病引起或伴有法布里病的神经病中的用途
KR20230134822A (ko) * 2022-03-15 2023-09-22 주식회사 녹십자 α-갈락토시다제 A의 융합단백질을 포함하는 액상 제제
KR20230134823A (ko) * 2022-03-15 2023-09-22 주식회사 녹십자 α-갈락토시다제 A의 융합단백질을 포함하는 동결 건조 제제

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE151113T1 (de) * 1992-01-23 1997-04-15 Merck Patent Gmbh Fusionsproteine von monomeren und dimeren von antikörperfragmenten
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
RU2002110121A (ru) * 1999-09-17 2004-03-10 Джитиси Байотерапьютикс, Инк. (Us) Слитые белки, полученные трансгенным способом
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2006108586A2 (en) * 2005-04-11 2006-10-19 Sanofi Pasteur Polymyxin b analogs for lps detoxification
PT1966245E (pt) * 2005-12-30 2011-08-31 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
JP5577243B2 (ja) * 2007-05-30 2014-08-20 ポステク アカデミー−インダストリー ファウンデイション 免疫グロブリン融合タンパク質
WO2015009052A1 (ko) * 2013-07-16 2015-01-22 일동제약 주식회사 하이브리드 면역글로불린 fc와 효소의 융합단백질
US20160193295A1 (en) * 2013-07-31 2016-07-07 Amgen Inc. Stabilization of fc-containing polypeptides
CA2972748A1 (en) * 2014-12-30 2016-07-07 Hanmi Pharm. Co., Ltd. Glucagon derivative having improved stability
AU2016334041B2 (en) * 2015-10-08 2023-02-09 Macrogenics, Inc. Combination therapy for the treatment of cancer
CN108367056B (zh) * 2015-12-08 2022-12-23 瑞泽恩制药公司 用于内化酶的组合物和方法
AR107483A1 (es) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
BR112020000273A2 (pt) * 2017-07-07 2020-07-14 Hanmi Pharm. Co., Ltd. proteína de fusão de enzima e seu método de preparação, composição farmacêutica, polinucleotídeo que codifica a proteína de fusão de enzima, vetor de expressão, transformante

Also Published As

Publication number Publication date
US20210009984A1 (en) 2021-01-14
KR20190076909A (ko) 2019-07-02
NZ765453A (en) 2024-03-22
PH12020550927A1 (en) 2021-05-10
AU2018388331A1 (en) 2020-07-02
SG11202005510SA (en) 2020-07-29
WO2019125059A1 (ko) 2019-06-27
CA3086474A1 (en) 2019-06-27
EP3708661A1 (en) 2020-09-16
EP3708661A4 (en) 2021-12-01
KR20230143985A (ko) 2023-10-13
AR113430A1 (es) 2020-04-29
JP2021507705A (ja) 2021-02-25
TW201934753A (zh) 2019-09-01
BR112020012346A2 (pt) 2020-11-24
CN111511910A (zh) 2020-08-07
KR102588611B1 (ko) 2023-10-16
MX2020006635A (es) 2020-12-10
JP7403455B2 (ja) 2023-12-22
IL275248A (en) 2020-07-30

Similar Documents

Publication Publication Date Title
EA202091239A1 (ru) Слитый белок на основе терапевтического фермента, имеющий новую структуру, и его применение
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
MX2023008559A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
EA202090084A1 (ru) Новый терапевтический ферментный слитый белок и его применение
EA201890790A1 (ru) Связывающие pd-1 белки и способы их применения
MD3303379T2 (ro) Agenți de legare TIGIT și utilizări ale acestora
EA201891420A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
EA201691795A1 (ru) Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина
EA201790895A1 (ru) Модифицированные полипептиды fgf-21 и их применение
EA202091342A2 (ru) Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения
PH12016500943A1 (en) Aplnr modulatros and uses thereof
EA201791773A1 (ru) Цистеиновая протеаза
EA201791984A1 (ru) Способы уменьшения уровня fc-содержащих агентов в сыворотке с применением fcrn-антагонистов
MX2022012042A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
EA201690114A1 (ru) КОНЪЮГАТ Fc ИММУНОГЛОБУЛИНА, СОХРАНЯЮЩИЙ СПОСОБНОСТЬ СВЯЗЫВАНИЯ С FcRn
CL2019003167A1 (es) Proteínas de unión al antígeno anti-jagged1.
BR112018005464A2 (pt) expressão de proteínas contendo fc
BR112021011595A2 (pt) Proteína biespecífica
EA201991768A1 (ru) Слитые белки на основе фактора ix и способы их получения и пути применения
EA202092327A1 (ru) Варианты lfa3 и их композиции и применение
EA202092639A1 (ru) Комбинации антительных вариантов и их применение
EA201991340A1 (ru) Способы индуцирования иммунологической толерантности к факторам свертывания крови
EA202090582A3 (ru) Полипептиды il-22, химерные белки il-22 fc и их применение
EA202092106A2 (ru) Модифицированные полипептиды fgf-21 и их применение